Tests and therapies for AMD will be developed by a €16m European-wide project involving City, University of London.
Novel approaches would be adopted to see if subtle changes in AMD can be accurately detected over time, studying 700 patients from 20 clinical sites across Europe.
Researchers at City will contribute to the MACUSTAR project over the course of a five-year project to help reduce the burden of AMD in healthcare, according to a statement. In total, €350,000 of the funding has been pledged to City, to assess a series of tests of visual function in conjunction with colleagues at UCL and Moorfields Eye Hospital.
By 2020, it was predicted 700,000 people would have late-stage AMD in the UK.
David Crabb, professor of statistics and vision research in the School of Health Sciences at City, said: ‘This is a very exciting European-wide collaboration. The data from the observational study is going to be quite unique. Our research lab offers particular expertise making us an important named partner. The consortium won through a long and highly competitive process in order to secure a massive funding budget. We are thrilled to bring some of these resources directly to City.’